Semaglutide

  • Semaglutide is a GLP-1 receptor agonist that mimics the action of the endogenous GLP-1 hormone. It stimulates insulin secretion in response to elevated blood glucose levels and suppresses glucagon secretion, helping to lower blood sugar levels. Semaglutide also slows gastric emptying, which reduces appetite and promotes weight loss. It enhances satiety by acting on the central nervous system, particularly in the brain’s appetite-regulation centers, making it effective in managing type 2 diabetes and obesity. Additionally, semaglutide has cardioprotective effects, reducing the risk of major cardiovascular events in patients with type 2 diabetes and high cardiovascular risk.

    • Promotes significant weight loss by reducing appetite and food intake.

    • Improves glycemic control in patients with type 2 diabetes.

    • Lowers HbA1c levels and improves long-term blood sugar control.

    • Reduces cardiovascular risks by lowering blood pressure and cholesterol.

    • Increases insulin sensitivity, improving glucose metabolism.

    • Decreases the risk of diabetes-related complications, such as neuropathy and retinopathy.

    • Supports weight maintenance after initial weight loss.

    • Reduces fatty liver disease by improving liver function and reducing liver fat.

    • Improves overall metabolic health, reducing the risk of metabolic syndrome.

    • Provides a long duration of action, with once-weekly dosing.

    • Type 2 Diabetes: Improves glycemic control in patients with type 2 diabetes.

    • Obesity: Promotes weight loss in individuals with obesity or overweight.

    • Cardiovascular Risk Reduction: Reduces risk factors like high blood pressure and cholesterol in at-risk patients.

    • Pre-diabetes: Helps prevent the progression of pre-diabetes to type 2 diabetes.

    • Non-Alcoholic Fatty Liver Disease (NAFLD): Reduces liver fat and improves liver function.

    • Metabolic Syndrome: Improves overall metabolic health and reduces associated risks.

    • Insulin Resistance: Enhances insulin sensitivity in patients with insulin resistance.

    • Polycystic Ovary Syndrome (PCOS): Helps manage weight and insulin sensitivity in women with PCOS.

    • Post-Bariatric Surgery: Supports weight maintenance after bariatric surgery.

    • Weight Loss Maintenance: Helps maintain long-term weight loss after an initial reduction.

    • Marso, S. P., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.

    •  Davies, M. J., et al. (2021). Efficacy of semaglutide for weight management in patients with obesity. JAMA, 325(14), 1403-1413.

    •  Blundell, J., et al. (2017). Effects of semaglutide on appetite control, energy intake, and body weight in subjects with obesity. Diabetes, Obesity & Metabolism, 19(9), 1242-1251.

    •  Wadden, T. A., et al. (2021). Semaglutide in the management of obesity: Clinical evidence and future perspectives. Obesity Reviews, 22(1), e13189.

    •  Holst, J. J., et al. (2020). Semaglutide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Diabetologia, 63(8), 1569-1580.

    •  Lingvay, I., et al. (2020). Semaglutide's role in the management of non-alcoholic fatty liver disease. Journal of Hepatology, 73(4), 758-765.

    •  Wilding, J. P., et al. (2021). Long-term effects of semaglutide in patients with obesity and metabolic syndrome. Lancet, 398(10295), 1014-1024.

    •  Nauck, M. A., et al. (2020). Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes and high cardiovascular risk. Cardiovascular Diabetology, 19(1), 32-40.

    •  Rubino, D., et al. (2021). Semaglutide for weight management in patients with and without type 2 diabetes. Diabetes Care, 44(2), 489-498.

    •  Franz, M. J., et al. (2021). Semaglutide for the treatment of obesity: A review of the clinical trial evidence. Current Obesity Reports, 10(2), 171-178.